Key Highlights

  • Loss per share was USD 0.20 against an estimate of a USD 0.22 loss.
  • Net loss was USD 9.88 million, compared with USD 16.37 million.
  • Research and development expenses were USD 2.18 million, compared with USD 11.63 million.
  • Cash and cash equivalents were USD 41.87 million at September 30, 2026.

Werewolf Therapeutics (NASDAQ:HOWL) reported a net loss of USD 9.88 million for the third quarter of 2026, compared with USD 16.37 million in the prior-year quarter. Net loss per common share, basic and diluted, was USD 0.20, compared with USD 0.36, against an estimate of a USD 0.22 loss.

For the nine months ended September 30, 2026, the net loss was USD 19.74 million, compared with USD 52.44 million, and net loss per share was USD 0.41, compared with USD 1.16.

Operating Results

Research and development expenses were USD 2.18 million, compared with USD 11.63 million, and general and administrative expenses were USD 7.88 million, compared with USD 4.09 million. Total operating expenses and the operating loss were USD 10.05 million, compared with USD 15.73 million.

Interest income was USD 183 thousand, compared with USD 697 thousand, and interest expense was nil, compared with USD 1.34 million. Weighted average shares outstanding were 48,599,066, compared with 45,804,042.

Nine-Month Results

Collaboration Revenue was USD 21.00 million for the nine months, with none in the quarter or the prior-year periods. Research and Development expenses for the nine months were USD 16.52 million, compared with USD 37.90 million, and general and administrative expenses were USD 20.65 million, compared with USD 13.36 million.

Total operating expenses were USD 37.17 million, compared with USD 51.26 million, and the operating loss was USD 16.17 million, compared with USD 51.26 million. The company recorded a loss on extinguishment of a note payable of USD 3.35 million, and interest expense was USD 1.84 million, compared with USD 3.91 million.

Restructuring and Balance Sheet

The filing states that in February 2026 the company adopted a restructuring plan to extend its Capital resources, in connection with initiating a process to explore strategic alternatives. The board approved a reduction in force representing 64% of the workforce in February 2026, and an additional reduction in force representing 36% of the workforce at that time occurred in May 2026.

Cash and cash equivalents were USD 41.87 million at September 30, 2026, compared with USD 57.05 million at December 31, 2025. Total Assets were USD 42.75 million, compared with USD 69.40 million. The filing describes contingent value rights that represent the right to receive contingent cash payments in respect of certain legacy assets, WTX-124 and WTX-330.

The filing states that under the collaboration agreement the company was responsible for certain preclinical development activities with respect to JZP898 and other development activities specified in mutually agreed development plans. In June 2024, the company executed a transfer agreement to assign its rights in a development agreement with a contract manufacturer of JZP898 to Jazz. The filing states that the company was eligible to receive up to USD 515.0 million in development and regulatory milestones and up to USD 740.0 million in sales-based milestones for all licensed products upon meeting certain conditions.

Werewolf Therapeutics Q3 2026 Earnings: Key Takeaways

Werewolf Therapeutics reported a third quarter 2026 net loss of USD 9.88 million and a loss per share of USD 0.20. Cash and cash equivalents were USD 41.87 million at September 30, 2026.